Trillium Therapeutics Inc (TRIL)

[NY1972]

0.2 mg/kg/week was well-tolerated and associated with predictable, transient thrombocytopenia - consistent with augmented systemic phagocytosis

decreasing volume and/or reduced metabolic activity over extended intervals of continued dosing were observed in several patients and one patient achieved a partial response.

single PR in Hodgkins @ .05 mg/Kg -68% relapsed

http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2016/Trillium-Presents-Initial-Data-From-Ongoing-Study-of-TTI-621-In-Patients-With-Advanced-Hematologic-Malignancies-At-The-American-Society-of-Hematology-Annual-Meeting/default.aspx